Wen Lin BS, MS, Ph.D

Dr. Wen Lin is a Senior Investigator I at the Novartis Institutes for BioMedical Research in East Hanover, NJ. Dr. Lin has extensive experience in both Gastroplus and Simcyp PBPK models, modeling preclinical and clinical data through all phases of drug development. Her key responsibilities include PK/PD, formulation and ADME studies needed for regulatory submission in all major disease areas, including application of pediatric PBPK models. Dr. Lin has been involved with the IQ Preclinical Workgroup for Polymorphism since 2013. Currently she serves as the Novartis representative to the Simcyp Paediatric Discussion Group. Dr. Lin received her B.S. in pharmacy and M.S. in pharmacology from the Second Military Medical University, China. She received her Ph.D. in pharmaceutics from Rutgers, the State University of New Jersey. Dr. Lin has authored/coauthored more than 20 publications.